Filing Details
- Accession Number:
- 0001209191-23-056455
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-22 16:15:09
- Reporting Period:
- 2023-11-21
- Accepted Time:
- 2023-11-22 16:15:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1231457 | Genelux Corp | GNLX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1937482 | Yong Yu | C/O Genelux Corporation 2625 Townsgate Road, Suite 230 Westlake Village CA 91361 | Vp, Clinical Trial Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-11-21 | 18,665 | $10.26 | 69,335 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.